CMC Biologics, Inc., a contract manufacturer of clinical and commercial manufacturing of therapeutic proteins, has entered into an agreement with Immunocore Limited, a UK-based biotechnology company focused on developing new treatments for cancer, viral infections and autoimmune diseases, for the process transfer and cGMP production of IMCgp100, Immunocore's lead product. IMCgp100 is a cancer immunotherapeutic based on proprietary platform T- cell receptor (TCR) technology.

Under the agreement, CMC Biologics will transfer and scale up Immunocore's manufacturing process for IMCgp100 into its microbial facility in Copenhagen, Denmark for cGMP manufacture to support Immunocore's clinical trials globally.

Source: CMC Biologics